Strong clinical progress in H1 and transformative collaboration with Gilead announced

• First half-year financial results:
  • Group revenues of €108.5 million

Operating loss of €97.6 million

Net loss of €95.9 million

Cash and cash equivalents on 30 June 2019 of €1,148 million

Further development of our broad and deep pipeline:

• Reported positive data with filgotinib in FINCH 1 and 3 Phase 3 trials in rheumatoid arthritis
• Completed recruitment of ROCCELLA Phase 2b trial with GLPG1972 in osteoarthritis, with Servier
• Initiated GECKO Phase 2 trial in atopic dermatitis with MOR106
• Initiated NOVESA Phase 2 trial with GLPG1690 in systemic sclerosis
• Initiated Phase 1 of GLPG3312, a first molecule aimed at the Toledo class of novel targets

Entered into transformative R&D collaboration with Gilead

Webcast presentation tomorrow, 26 July 2019, at 14.00 CET/8 AM ET, www.glpg.com, [phone], code 6080337

Mechelen, Belgium; 25 July 2019, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.

"It's our 20th anniversary year, and what a year so far," said Onno van de Stolpe, CEO. "Our partner Gilead and we announced a transformational global R&D collaboration on 14 July, securing our company's independent R&D for years to come. This agreement is about maximizing innovation based on the identification and development of new mode of action medicines. In Q1 2019, together with Gilead, we announced positive data from the first 24 weeks of the FINCH 1 and 3 Phase 3 trials in rheumatoid arthritis, bringing our total patient exposure to filgotinib to beyond 3,000 patient years. The FINCH trial safety data was consistent with the long-term safety data observed in the DARWIN 3 long term extension trial, further strengthening our understanding of the potential impact of selective JAK1 inhibition on patient well-being. Our research engine continues to be extremely productive, with additional late stage trial starts, completion of recruitment in ROCCELLA, and our first Phase 1 trial from the next-generation Toledo program for inflammation."